tiprankstipranks
Aptose Biosciences Issues Regulation FD Disclosure Statement
Market News

Aptose Biosciences Issues Regulation FD Disclosure Statement

Aptose Biosciences (APTO) has released an update to notify the public and investors about a regulation fd disclosure.

Pick the best stocks and maximize your portfolio:

On January 26, 2024, the Registrant released a press statement. The information in the release, although attached to official documentation, is not to be considered “filed” under the Securities Exchange Act of 1934, nor is it to be incorporated by reference into any other filings, unless explicitly stated in such filings.

For further insights into APTO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAptose Biosciences Advances TUS as AML Therapy
TheFlyAptose Biosciences announces clinical data on tuspetinib
TipRanks Canadian Auto-Generated NewsdeskAptose and NCI Collaborate on Cancer Drug Trials
Go Ad-Free with Our App